[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.62.139. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1980

Effectiveness of Triglycyl Vasopressin in Persistent Hematuria Associated With Sickle Cell Hemoglobin

Author Affiliations

From the Departments of Pediatrics (Drs John and Rosenthal), Medicine (Dr Schade), and Radiology (Dr Spigos), and the Sickle Cell Center of the Abraham Lincoln School of Medicine (Dr Schade), University of Illinois College of Medicine, Chicago; and the Department of Physiology, Mount Sinai School of Medicine, New York (Dr Cort).

Arch Intern Med. 1980;140(12):1589-1593. doi:10.1001/archinte.1980.00330230035011
Abstract

• Two cases of persistent hematuria associated with the presence of sickle cell hemoglobin were treated intravenously with triglycyl vasopressin, a drug not previously used for this condition. One patient, a 16-year-old boy, had hemoglobin SC, and the other patient was a 30-year-old woman with hemoglobin AS. Both patients had a history of severe hematuria persisting over several months, resistant to the usual forms of therapy, and requiring numerous tranfusions. In each patient, the condition responded to intravenous triglycyl vasopressin therapy, with cessation of hematuria. Experimental studies in dogs indicate that triglycyl vasopressin reduces renal blood flow substantially. Further trial of triglycyl vasopressin in severe hematuria associated with the presence of sickle cell hemoglobin appears to be indicated.

(Arch Intern Med 140:1589-1593, 1980)

×